See Inside November 2010

Halting the World's Most Lethal Parasite: Immunizing Mosquitoes and Other "Crazy" Antimalaria Ideas

A new malaria vaccine, a plan to immunize mosquitoes, and other "crazy" ideas have brightened prospects for vanquishing this killer

More In This Article

Right now, somewhere in the world—in a petri dish in Baltimore, maybe, or in the salivary glands of a laboratory-bred mosquito in Seattle, or in the bloodstream of a villager in Ghana—resides a chemical compound that could help eradicate human history’s biggest killer. Scientists have many promising malaria vaccine candidates in the works, and for the first time one has reached advanced human trials. If it or another candidate is even partly effective in people, it could save the lives of millions of children and pregnant women. It would be the only vaccine yet developed against a human parasite, an achievement of Nobel caliber. And it could, in its first-generation form, be distributed in Africa as soon as 2015.

“If all goes well, five years from today, a vaccine could start being implemented in a wide way in six- to 12-week-old children,” says Joe Cohen, a scientist who is leading some of the most promising research. “It is a fantastic achievement. We are all very proud of that.” This is an extraordinary moment for malaria vaccine research. So why isn’t Regina Rabinovich singing from the rooftops?

This is only a preview. Get the rest of this article now!

Select an option below:

Customer Sign In

*You must have purchased this issue or have a qualifying subscription to access this content

It has been identified that the institution you are trying to access this article from has institutional site license access to Scientific American on
Click here to access this article in its entirety through site license access.

Rights & Permissions
Share this Article:


You must sign in or register as a member to submit a comment.
Scientific American Holiday Sale

Scientific American Mind Digital

Get 6 bi-monthly digital issues
+ 1yr of archive access for just $9.99

Hurry this offer ends soon! >


Email this Article


Next Article